A Phase 2 Open-label, Prospective, Randomized Study of Inebilizumab, VIB4920, or the Combination to Evaluate Safety and Tolerability in highly sensitized candidates awaiting kidney transplantation from a deceased donor

Project: Research project

Project Details

StatusFinished
Effective start/end date12/13/19 → 6/30/23

Funding

  • Viela Bio, Inc (Agmt 12/13/19)